Liver/Biliary Disorders News

Screening for hepatocellular carcinoma is critical in high-risk patients, according to a presentation at GUILD conference 2022.

Without approved treatment options for hepatitis D, screening has largely fallen by the wayside; however, promising therapies in phase 3 trials may shift that paradigm, according to a presenter at the GUILD Conference.

The emerging treatment landscape of nonalcoholic steatohepatitis has “exploded” as understanding of the pathogenesis grows, according to a presenter at GUILD 2022.

Albireo Pharma Inc. announced the publication of the PICTURE study, which assessed the impact that progressive familial intrahepatic cholestasis has on caregivers, according to a company press release.

Universal screening for hepatitis C virus detected more infections in pregnant people, as well as transmission to infants, according to a presenter at the Conference on Retroviruses and Opportunistic Infections.

Vibration-controlled transient elastography and fibrosis-4 index are effective alternatives to liver biopsy when evaluating risk for liver-related events in patients with nonalcoholic fatty liver disease, according to study results.

Molecules in saliva may be highly sensitive and specific noninvasive biomarkers of hepatocellular carcinoma, according to a study published in PeerJ.

The majority of liver transplant recipients are able to produce a functional antibody response to COVID-19 infection, according to data published in Gut.

Among adults who undergo radioactive iodine therapy for differentiated thyroid cancer, risk for hepatic dysfunction is elevated for men and all with low free thyroxine or high triglycerides, according to study data.

The United Network for Organ Sharing database on acute-on-chronic liver failure categorization in liver transplant patients is discordant with manual chart review and demonstrates the need for policy reform, according to study results.